Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: ztect who wrote (1777)	2/21/1999 5:01:00 PM
From: Wolff	Read Replies (1) \| Respond to of 2135

My understanding is the BMY had access to the Folkman Technology, and they are walking away. I am troubled by some unexplained things. A partner BMY pulls out and says that they don't feel that AS meets the criteria for going to trials, and ENMD is silent on the issues. Other reports indicate that it is the manufacuring which will be the problem. Which is it, and why isn't ENMD acknowledging the issues. No response IMO means that they agree with the long term problems, or are denying the facts. I don't want my investments to deny facts. At a minimum they need to be forthcoming, they partnered with a Big Drug company for reasons, experience, cash, resources. If they pull out it is not a small deal. And when the Big Partner says that they don't feel the drug meets the needs for clinical trials, that needs to be spoken too. BMY basically says they don't believe in your direction and products, and you (ENMD) say nothing! We have got a major item that remains unsettled. Then the next day the NCI goes into the orginal lab and duplicates the results. Remember that ENMD list the NCI as a partner on their web site. The timing troubles me, one nice PHD supporting another nice PHD? How do we explain the timing if the NCI flying in? When I go to the ENMD web site I can see information about AngiostatinTM in the information section of the antiangiogenic products and technoloy. But to the EndostatinTM protein it just says the name. AS has studies and verbage written, while ES has nothing of the sort. This make me think that AS was more the emphasis and believe, and now that BMY is gone the focus will go to ES. But they got to update the WWW site, and more time-pain-stakenly get some articles published in the journals. Ztect, there are major events happening that neither you nor the company are addressing. Bye-Bye!